C Christofer Juhlin
Overview
Explore the profile of C Christofer Juhlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
2238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Condello V, Marchettini C, Ihre-Lundgren C, Nilsson J, Juhlin C
Endocr Pathol
. 2025 Feb;
36(1):4.
PMID: 39982585
Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer (WDTC) and generally has a favorable prognosis. However, subsets of these tumors can metastasize, leading to aggressive...
2.
Lundgren Mortensen A, Berglund H, Jha P, Stenman A, Selvaraju R, Lundqvist H, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39976160
Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for...
3.
4.
Mete O, Juhlin C
Best Pract Res Clin Endocrinol Metab
. 2024 Nov;
38(6):101958.
PMID: 39609157
Pheochromocytomas and paragangliomas (PPGLs) represent a unique subset of neuroendocrine neoplasms (NENs) characterized by their genetic diversity and potential for catecholamine secretion. Similar to epithelial NENs, all PPGLs are classified...
5.
Condello V, Juhlin C
Eur Thyroid J
. 2024 Nov;
13(6).
PMID: 39601261
In recent years, germline mutations in the microRNA (miRNA) processor genes DICER1 and DGCR8 have been coupled to the development of thyroid follicular nodular disease (TFND), thereby casting new light...
6.
Branstrom R, Zedenius J, Shabo I, Lindskog M, Juhlin C
Case Rep Oncol
. 2024 Oct;
17(1):1124-1130.
PMID: 39474531
Introduction: Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer in adults, presents significant challenges owing to its resistance to conventional therapies. Standard treatment primarily revolves...
7.
Hellgren L, Stenman A, Jatta K, Condello V, Larsson C, Zedenius J, et al.
Endocr Pathol
. 2024 Oct;
35(4):411-418.
PMID: 39363120
De-escalation of thyroid cancer treatment is crucial to prevent overtreatment of indolent disease, but it remains important to identify clinically aggressive cases. TERT promoter mutations are molecular events frequently associated...
8.
Backman S, Botling J, Nord H, Ghosal S, Stalberg P, Juhlin C, et al.
J Pathol
. 2024 Oct;
264(4):357-370.
PMID: 39360347
Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular may progress from a low/intermediate to a high-grade...
9.
Xu Y, Gao J, Wang N, Zedenius J, Nilsson I, Lui W, et al.
J Clin Endocrinol Metab
. 2024 Aug;
110(3):693-705.
PMID: 39183149
Context: BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma (PTC) have a synergistic effect on prognosis. This effect is believed to arise from MAPK activation triggered by BRAFV600E, leading...
10.
Juhlin C, Mete O
Turk Patoloji Derg
. 2024 Aug;
40(3):143-148.
PMID: 39171856
Pheochromocytoma and abdominal paraganglioma (PPGL) are rare catecholamine-producing, keratin-negative, non-epithelial neuroendocrine neoplasms characterized by a unique association with syndromic diseases caused by constitutional mutations in a wide range of susceptibility...